Aquestive Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Aquestive Therapeutics, Inc. (AQST) reported Earnings Per Share, Basic and Diluted of -$0.60 per share for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-03-09
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.60.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.49.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.07.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.49.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.66.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$2.61.
- Aquestive Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$2.96.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$0.60 10-K · filed 2021-03-09 | -$1.66 10-K · filed 2021-03-09 | ||
| 2020-09-30 | -$0.49 10-K · filed 2021-03-09 | -$1.05 10-Q · filed 2020-11-04 | ||
| 2020-06-30 | -$0.07 10-K · filed 2021-03-09 | -$0.56 10-Q · filed 2020-08-04 | ||
| 2020-03-31 | -$0.49 10-K · filed 2021-03-09 | |||
| 2019-12-31 | -$0.48 10-K · filed 2021-03-09 | -$2.61 10-K · filed 2021-03-09 | ||
| 2019-09-30 | -$0.74 10-K · filed 2021-03-09 | -$2.15 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | -$0.82 10-K · filed 2021-03-09 | -$1.41 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | -$0.59 10-K · filed 2021-03-09 | |||
| 2018-12-31 | -$0.56 10-K · filed 2020-03-11 | -$1.19 derived: net income ÷ weighted average shares · filed 2020-03-11 | -$2.90 derived: net income ÷ weighted average shares · filed 2020-03-11 | -$2.96 10-K · filed 2020-03-11 |
| 2018-09-30 | -$0.64 10-K · filed 2020-03-11 | -$2.41 derived: net income ÷ weighted average shares · filed 2019-11-05 | -$2.45 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$1.90 10-K · filed 2020-03-11 | -$1.89 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $0.27 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |